United for Action: Avitia and Colorectal Cancer Canada Advance Patient Outcomes

Mar 2025

United for Action: Avitia and Colorectal Cancer Canada Advance Patient Outcomes

While colorectal cancer remains one of the most pressing health challenges, innovation and collaboration are changing the landscape in early detection and treatment. As Colorectal Cancer Awareness Month begins, Avitia is proud to stand with Colorectal Cancer Canada in the fight against this high-burden disease. Avitia is a Canadian company that’s dedicated to advancing cancer diagnostics through NGS-based, AI-driven molecular testing. Avitia’s work builds on years of genomic testing and AI technology that identifies key tumor mutations in tissue or blood specimens — including those specific to colorectal cancer. With targeted, data-driven care pathways, Avitia prioritizes patient well-being by minimizing the need for invasive treatments. Now Canadian patients have access to precision diagnostics using non-invasive liquid biopsy, which has already helped thousands of patients nationally — as well as globally . By focusing on improving access to timely and precise testing, Avitia is committed to supporting patients and healthcare providers in making informed treatment decisions.

Colorectal cancer remains one of the most common and deadly cancers, which is why Avitia is deeply focused on this cancer providing information on key biomarkers, such as KRAS, BRAF, HER2, and MSI. According to the Canadian Cancer Statistics Advisory Committee, ~25,200 Canadians were diagnosed with colorectal cancer, representing ~10% of all new cancer cases in 2024. However, it’s important to remember that this isn’t just affecting an elderly population. About 30% of early-onset colorectal cancer cases develop in individuals with a family history of the disease, which is why timely detection is critical to improving outcomes.

Through supporting efforts to improve access to testing, Avitia aligns with CCC’s mission to ensure that all patients receive timely, high-quality cancer care​ — reducing the incidence and mortality of colorectal cancer in Canada. To achieve this, Avitia brings advanced molecular testing directly to labs, helping healthcare teams provide faster, more accurate patient-centric care. Its on-site testing solutions reduce waiting times, cut diagnostic costs, and give doctors the information they need to help patients begin targeted treatments sooner.

Together, Avitia and CCC are committed to advancing solutions that improve outcomes for colorectal cancer patients. While we’ll be wearing Blue (#dressinblue) all March to showcase Avitia’s solidarity, we’ll continue this fight with CCC year-round to bring an end to this Preventable, Treatable, and Beatable disease.

Learn more about Avitia’s work at www.avitia.bio.